Maryland-based Kaigene, Inc. has granted Taisho Pharmaceutical Co., Ltd. exclusive rights to develop, register, and commercialize KG006 (CT-P77) in Japan, completing the territorial licensing map for its lead FcRn inhibitor program and creating a three-way multinational clinical trial collaboration with South Korea-based Celltrion (KRX: 068270).
Under the agreement, Kaigene receives a USD 5 million upfront payment and is eligible for up to USD 22 million plus JPY 57.5 billion (approximately USD 351 million) in development, regulatory, and commercial milestone payments, plus tiered royalties on Japanese net sales. The dual-currency milestone structure — with USD-denominated development and regulatory payments alongside JPY-denominated commercial milestones — introduces foreign exchange exposure for Kaigene but reflects Taisho's preference for tying sales-based obligations to domestic currency performance.
The deal follows Kaigene's November 2025 global licensing agreement with Celltrion, under which Celltrion obtained worldwide rights to KG006 excluding Japan and Greater China, alongside worldwide rights to KG002, for USD 8 million upfront and up to USD 736 million in milestones across both assets. With Japan now assigned to Taisho, Greater China rights for KG006 remain the only major unpartnered territory.
KG006 - which is still in the preclinical stages - is described by Kaigene as a next-generation human neonatal Fc receptor (hFcRn) inhibitor with a novel antibody structure, designed to deliver deep pathogenic IgG degradation with extended durability and subcutaneous self-administration. The FcRn inhibitor class has moved from zero to three FDA approvals since 2021 — efgartigimod alfa (argenx), rozanolixizumab (UCB), and nipocalimab (Johnson & Johnson) — validating the mechanism while crowding the competitive landscape. Efgartigimod is already approved and commercialized in Japan for generalized myasthenia gravis and immune thrombocytopenia. Immunovant's IMVT-1402, also positioned as a next-generation FcRn inhibitor, is in Phase III trials across multiple indications and represents the most direct pipeline competitor.
The structural novelty of the Taisho deal lies less in its economics than in its three-way clinical architecture. Taisho is expected to participate in a multinational Phase III study led by Celltrion, creating a coordinated development framework across the US, South Korea, and Japan at a preclinical-to-early-clinical stage. Most comparable Japan territorial licenses do not embed the local partner into a coordinated global Phase III design at signing; the arrangement reduces Kaigene's Phase III cost burden and potentially accelerates PMDA review by integrating Japanese patients into a global trial dataset.